https://phrma.org/blogs/rss PhRMA Blog RSS Feed for Sitecore Send Repeatable Campaigns en-us 13868 https://phrma.org/blog/voters-continue-to-voice-their-concerns-on-government-price-controls Tom Wilbur, July 24, 2026 Across the country and building on a cohort of voices from earlier this year, Voters for Cures advocates are continuing to speak out against government price controls like Most Favored Nation (MFN).   Fri, 24 Jul 2026 14:05:36 GMT 13854 https://phrma.org/blog/icymi-fox-business-hosts-call-340b-a-rotten-system-and-cash-cow-for-hospitals Eliza Maciag, July 23, 2026 Scrutiny of the 340B program continues to gain traction in Washington and in the media. Across multiple Fox Business segments—including Varney & Co., Mornings with Maria and The Big Money Show—hosts and correspondents described the program as a “rotten system” and a “cash cow” for hospitals while highlighting concerns that 340B lacks accountability and may benefit hospitals more than patients. Thu, 23 Jul 2026 04:00:00 GMT 13852 https://phrma.org/blog/medicare-part-d-at-20-building-on-a-strong-foundation Matthew Norawong, July 23, 2026 This year marks the 20th anniversary of Medicare Part D, a landmark benefit that transformed access to prescription medicines for millions of seniors and people with disabilities. As Medicare reaches its 61st year, Part D remains one of the program's most important achievements. Thu, 23 Jul 2026 04:00:00 GMT 13860 https://phrma.org/blog/message-to-usaging-providers-are-raising-concerns-about-coverage-barriers Sharon Lamberton, MS, RN , July 22, 2026 As a nurse, I know access to the right medicine at the right time can make a meaningful difference for patients managing chronic and complex conditions. This week, I joined USAging at their Answers on Aging conference to continue a conversation that providers and patients across the country are raising their voices on.  Wed, 22 Jul 2026 19:09:35 GMT 13851 https://phrma.org/blog/hpv-vaccination-helps-prevent-cervical-cancer-deaths Carolyn Ha, July 21, 2026 A new study published in The Lancet offers some of the strongest real-world evidence to date that vaccination against human papillomavirus (HPV) is saving lives. Tue, 21 Jul 2026 16:35:06 GMT 13841 https://phrma.org/blog/mass-compounding-puts-patients-at-risk Kristen Booze, July 16, 2026 Drug compounding is generally a practice in which a licensed pharmacist or physician mixes, alters or combines ingredients to create a medication tailored to the needs of an individual patient. While drug compounding can serve a role in limited situations, like for a patient with an allergy to an ingredient in an FDA-approved product, mass compounding under the guise of “personalization” goes well beyond these narrow circumstances. The rapid growth of mass compounding of knockoff medicines under the guise of “personalization” raises serious concerns about safety and oversight.  Thu, 16 Jul 2026 04:00:00 GMT 13817 https://phrma.org/blog/setting-the-record-straight-3-facts-about-drug-patents Andrew Powaleny, July 13, 2026 As critics once again target the intellectual property (IP) system, it is important to set the record straight. Mon, 13 Jul 2026 04:00:00 GMT 13818 https://phrma.org/blog/new-pbm-principles-don-t-change-the-fundamental-challenge-access-to-lower-cost-medicines Caroline Dunne, July 10, 2026 Facing growing scrutiny for blocking and denying access to care, PBMs are rolling out a new set of “policy principles” meant to shift the blame. But strip away the rhetoric, and the reality is unchanged: the very middlemen claiming to promote affordability are the ones driving patients’ frustrations, putting up barriers, delaying treatment and too often standing between people and the care they need. PBMs say they’re for lowering costs, but their own policies often limit access to low-cost medicines that patients have come to rely on in the form of generics and biosimilars. Fri, 10 Jul 2026 14:39:00 GMT 13799 https://phrma.org/blog/how-250-years-of-smart-policy-built-america-s-biopharmaceutical-edge Stephen J. Ubl, July 2, 2026 America didn't stumble into becoming the world's leading engine of medical innovation. It was deliberately built, through decades of smart policy choices that rewarded discovery and created a valuable scientific ecosystem that has delivered breakthroughs for patients. Thu, 02 Jul 2026 04:00:00 GMT 13788 https://phrma.org/blog/staffing-up-building-the-future-biopharma-workforce-to-keep-america-in-the-lead Drew Voytal, June 29, 2026 A new report from TEConomy shows how the biopharmaceutical industry is co-investing in the American workforce, not simply building new facilities. Mon, 29 Jun 2026 14:35:51 GMT 13787 https://phrma.org/blog/340b-s-reality-a-booming-business-for-hospitals-pharmacies-and-corporate-giants Molly Jenkins, June 25, 2026 A new Drug Channels analysis shows how the 340B program has morphed into a large and growing business model for hospitals, pharmacies and some of the country’s biggest corporations. It has evolved far from a niche safety-net program for clinics and a small number of hospitals. Thu, 25 Jun 2026 17:50:19 GMT 13786 https://phrma.org/blog/guest-blog-price-controls-won-t-lower-costs-when-insurers-control-access Guest Contributor, June 25, 2026 Voters for Cures works to drive patient-centered progress in innovation, affordability and access and pushes for necessary, positive and long-term change to better address the needs of diverse patient communities. As policymakers continue to debate harmful price-setting policies in the form of Most Favored Nation Pricing (MFN), hear what advocate Lauren C. from North Carolina has to say.  Thu, 25 Jun 2026 04:00:00 GMT 13785 https://phrma.org/blog/insurers-are-blaming-medicines-for-premium-hikes-in-massachusetts-the-state-s-own-data-suggests-otherwise Will May, June 24, 2026 Commercial insurers are seeking double-digit premium increases in Massachusetts and pointing the finger at prescription medicines. But the state’s numbers don't back it up. Wed, 24 Jun 2026 04:00:00 GMT 13778 https://phrma.org/blog/340b-s-lack-of-guardrails-lets-big-hospital-systems-turn-it-into-an-oversight-free-revenue-stream Eliza Maciag, June 22, 2026 A new Milbank Quarterly paper ends the debate: 340B was never intended to be a hospital markup program that drives up costs for patients, employers and taxpayers.  Mon, 22 Jun 2026 20:07:17 GMT